00874 白雲山
公司資料 - 損益表
廣州白雲山醫藥集團股份有限公司 股票編號: 00874
GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS COMPANY LIMITED 集團網址: http://www.gybys.com.cn
2026/06 - 中期
人民幣(K¥)
與去年中期比較 2025/12
人民幣(K¥)
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
營業額 / 收益42,090,9550.613%77,656,11074,992,82075,515,40470,788,155
銷售成本(34,821,047)1.901%(65,045,061)(62,472,769)----
毛利7,269,908-5.133%12,611,04912,520,052----
 
投資物業公平值變動及減值------------
其他項目公平值變動及減值(141,951)-14.754%(205,642)(445,927)(48,028)(56,721)
出售項目溢利 / (虧損)939-74.162%107,74111,11912,027690
其他非經營項目------------
分佔聯營公司及共同控制公司業績36,121--5,935(51,618)107,888136,588
除稅前溢利 / (虧損)2,601,697-15.814%3,689,9263,607,5805,110,4985,043,244
稅項(442,930)-13.909%(629,216)(606,849)(851,170)(789,874)
已終止經營業務溢利 / (虧損)------------
非控股權益(62,849)5.132%(77,597)(165,235)(203,649)(286,848)
其他項目------------
股東應佔溢利 / (虧損)2,095,918-16.701%2,983,1142,835,4964,055,6793,966,522
 
淨財務支出 / (收入)179,67545.914%281,23838,229(19,561)(162,456)
折舊及攤銷488,3922.166%955,849936,198985,320793,656
董事酬金----1,7943,6785,1332,663
 
核數師意見不適用--無保留意見無保留意見無保留意見無保留意見 (修定報告)
 
市場價值指標
每股盈利 (仙)128.900--183.500174.400249.500244.000
每股派息 (仙)30.000--85.00080.00074.90073.200
派息比率 (%)23.274%--46.322%45.872%30.020%30.000%
每股現金流 ($)-----0.1432.1172.5244.305
每股帳面資產淨值 ($)24.070--23.24322.08421.47819.723
 

Copyright © 2026 ET Net Limited.
All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.